Health-care companies fell, but not by as much as the broad market, as traders rotated into sectors less sensitive to inflation and fuel costs.
Tyra Biosciences fell sharply after the performance of a bladder-cancer drug candidate in a mid-stage clinical trial disappointed investors.
Johnson & Johnson, which is also developing a bladder-cancer treatment, fell slightly.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.